Home › NCT06223607

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* ≥ 18 years
* PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
* Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
* At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor

Exclusion Criteria:

* Death within 48 hours post-PCI
* DAPT prior to cardiac catheterization

About the study

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Sponsor: Methodist Health System · Participants: 300 · Started: Aug 22, 2022

Contact the study team

• Bethany Brauer · Phone: 214-947-4681
• Colette Ngo Ndjom · Phone: 214-947-1289

Official record on ClinicalTrials.gov — NCT06223607

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.